Business
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recogniz...
About this update from Go Metals Corp.
[{"type":"text","content":"Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm\n\n\n\n NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims Organon & Co. (NYSE:OGN), Landstar System, Inc. (NASDAQ:LSTR), Arvinas, Inc. (NASDAQ:ARVN), and GoHealth, Inc. (NASDAQ:GOCO). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.\n \n\n\n Organon & Co. (NYSE:OGN)\n \n\n\n On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. The majority of the decline was attributed to a 17% y/y decline in Biosimilars and an 11% y/y drop in Established Brands on the loss of Atozet exclusivity. On the back of these results, OGN announced it was cutting its dividend from $0.28 to $0.02 (a decrease of more than 92%).\n \n\n Following this news, the price of Organon stock fell more than 28% on the same day.\n \n\n For more information on the Robinhood investigation go to:\n \n https://bespc.com/cases/OGN\n \n\n\n\n Landstar System, Inc. (NASDAQ:LSTR)\n \n\n\n On April 2, 2025, Landstar revealed that it had \"identified a significant supply chain fraud.\" The Company said \"this fraud may adversely affect Landstar's 2025 first quarter earnings per share in a range of $0.35 to $0.50.\" As a result, Landstar withdrew its previously issued first quarter 2025 earnings guidance. Following this news, Landstar stock dropped. Then, on April 25, 2025, Landstar announced that it would be unable to timely file its quarterly report as it had not yet completed its ongoing evaluation of certain accounting and internal control matters related to the previously identified fraud. Following this news, Landstar stock again dropped, thereby damaging investors.\n \n\n For more information on the Landstar investigation go to:\n \n https://bespc.com/cases/LSTR\n \n\n\n\n Arvinas, Inc. (NASDAQ:ARVN)\n \n\n\n On May 1, 2025, Arvinas and its partner Pfizer announced that they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated two plann...